Dec. 17, 2021— The success of the 340B drug pricing program in providing crucial care to those in need is backed up by both a growing body of research and the personal testimonials of patients and health care providers. Behind that success are dedicated professionals who help ensure that safety-net hospitals run effective, efficient, and compliant 340B programs. Throughout … [Read more...]
340B Transparency Efforts Uncovering More Drug Company Overcharges
Dec. 8, 2021– In the nearly three years since the Health Resources & Services Administration (HRSA) launched its 340B drug pricing program ceiling price website, 41 drug companies have acknowledged that they overcharged 340B hospitals, health centers, and clinics and would refund those affected. This contrasts with only seven such reports in the two years prior to the … [Read more...]
We Celebrate Rural Health Day by Protecting 340B
Nov. 18, 2021– The patient care mission of 340B hospitals serving rural areas of the U.S. takes on a special importance when one considers that in many cases, they are the only providers in a position to offer certain types of needed care. On this National Rural Health Day, we reflect on the crucial nature of the role rural hospitals play, the continuing challenges they face, … [Read more...]
340B Hospitals Continue to Answer the Call to COVID Service
Nov. 12, 2021– In January 2021, St. Luke’s Health System Senior Director of Pharmacy Scott Milner was the featured guest on 340B Health’s podcast, 340B Insight, to discuss the initial rollout of COVID-19 vaccines throughout the U.S. “For me, the vaccine's greatest side effect is hope,” Scott said at the time. Fast forward 10 months, and much has happened in the national … [Read more...]
Recognizing Patients on 340B’s Anniversary
Nov. 4, 2021 – Jennifer Gallagher was aware of the 340B drug pricing program as the lead pharmacy technician at Parkview Medical Center in Pueblo, Colo. But she says it was not until she had her own medical challenges that she came to understand what the program means to patients. Today she views 340B as playing a pivotal role in her ability to stay healthy and continue working … [Read more...]
Eli Lilly Again Reports Big Revenue Gains From 340B Denials
Nov. 1, 2021– The first drug company to deny 340B drug pricing program discounts to safety-net hospitals, health centers, and clinics saw its U.S. revenues jump 26% in the third quarter of 2021, thanks in part to the higher prices it is charging for diabetes drugs sold to 340B providers. In a public financial report, Eli Lilly said its third-quarter U.S. revenue totaled … [Read more...]
Faces of 340B: Community Pharmacy Partnerships Benefit Patients with Diabetes
Oct. 28, 2021 – Courtney Riddle’s patient was at a family-owned pharmacy in Magnolia, Ark., where she always picked up her medications, including the diabetes drug Jardiance that was helping to control her blood sugar levels. The patient’s out-of-pocket cost typically was $16.43 for a month’s supply, but this time it was much different. The patient received a note that said … [Read more...]